|
Gene: ZNF749 |
Gene summary for ZNF749 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF749 | Gene ID | 388567 |
Gene name | zinc finger protein 749 | |
Gene Alias | ZNF749 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O43361 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388567 | ZNF749 | S016 | Human | Liver | HCC | 6.86e-16 | 4.48e-01 | 0.2243 |
388567 | ZNF749 | S027 | Human | Liver | HCC | 1.31e-05 | 3.07e-01 | 0.2446 |
388567 | ZNF749 | S028 | Human | Liver | HCC | 1.62e-09 | 3.26e-01 | 0.2503 |
388567 | ZNF749 | S029 | Human | Liver | HCC | 3.24e-08 | 3.24e-01 | 0.2581 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF749 | SNV | Missense_Mutation | c.1315G>C | p.Glu439Gln | p.E439Q | O43361 | protein_coding | deleterious(0.02) | benign(0.125) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.387G>T | p.Lys129Asn | p.K129N | O43361 | protein_coding | tolerated(0.06) | benign(0.078) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ZNF749 | insertion | Frame_Shift_Ins | novel | c.2030_2031insAACAAAGGCC | p.Arg678ThrfsTer4 | p.R678Tfs*4 | O43361 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
ZNF749 | SNV | Missense_Mutation | c.436C>T | p.His146Tyr | p.H146Y | O43361 | protein_coding | tolerated(0.06) | benign(0.019) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.941N>C | p.Val314Ala | p.V314A | O43361 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF749 | SNV | Missense_Mutation | c.2086C>T | p.His696Tyr | p.H696Y | O43361 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.95N>C | p.Leu32Pro | p.L32P | O43361 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.1111N>G | p.Arg371Gly | p.R371G | O43361 | protein_coding | tolerated(0.5) | benign(0.358) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.2096N>C | p.Ser699Thr | p.S699T | O43361 | protein_coding | tolerated(0.17) | benign(0.018) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF749 | SNV | Missense_Mutation | c.874C>T | p.Leu292Phe | p.L292F | O43361 | protein_coding | tolerated(0.69) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |